ClinicalTrials.gg
TerminatedNCT05918978POTSUpdated Oct 23, 2025Results posted

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

A Phase 2 interventional study of Efgartigimod in Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome, sponsored by argenx. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-23.

Sponsored by argenx · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to the phase 2 results of the main study (ARGX-113-2104) showing that efgartigimod-treated PC-POTS patients had no clinically meaningful improvement, the decision has been made to terminate this open-label extension study (ARGX-113-2105) study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States — 19 open to participants now, 42 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · United States.

Enrollment
35th of 67
33 · median 36
Started
2023
with 8 others
Phase 2
10 of 92
3 open now
Registered
73rd of 92
by date
Lead sponsor
2 of 92
argenx

Among the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, this one is the 35th largest by enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2023, is one of 10 in phase 2, and was the 73rd registered.

Postural Orthostatic Tachycardia Syndrome

136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.

Browse Postural Orthostatic Tachycardia Syndrome studies →

Open to participants now

19 of the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, or all of them as a file.
02

Study summary

The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.

Read the detailed description

Study ARGX-113-2105 is a long-term, single-arm, open-label, multicenter extension of the ARGX-113-2104 study, designed to evaluate the long-term safety of efgartigimod IV in adult patients with PC-POTS. Participants will be enrolled from both active and placebo arms of the ARGX-113-2104 study and will receive efgartigimod IV 10 mg/kg in the extension study without knowledge of their prior treatment arm. To be eligible to enroll in this study, participants must have completed the 24-week treatment period of the ARGX-113-2104 study and must not have permanently discontinued the IMP in that study.

03

Conditions studied

  • Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

Keywords

  • Tachycardia Post-COVID
  • Postural Orthostatic Tachycardia Syndrome efgartigimod
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant has completed the ARGX-113-2104 study without permanent discontinuation of IMP and agrees to directly roll over into the extension study without discontinuation of IMP.
  2. The participant signs the form, and can comply with OLE study (ARGX-113-2105) protocol requirements.
  3. The participant agrees to use consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Contraceptive requirements are provided.
  4. Female participants of must have a negative urine pregnancy test at baseline before receiving IMP.

Exclusion criteria

Exclusion Criteria:

  1. The participant has a condition, based on the judgement of the Study Investigator, eg, laboratory abnormalities, 12-lead readings, concomitant medical disease(s), etc., which may place them at undue risk or confound interpretation of study data.
  2. The participant intends to become pregnant or start breastfeeding during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Efgartigimod

    Receive efgartigimod IV 10mg/kg infusions during a treatment period of 48 weeks

    Drug: Efgartigimod

Interventions

  • Participants will receive efgartigimod IV 10 mg/kg open label, respectively.

06

What researchers measure

Primary outcomes

  1. Number of Participants With TEAEs, TESAEs and TEAESIs

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. An adverse event of special interest (AESI) was an AE of scientific and medical concern specific to the sponsor's product or program. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration.

    Time frame: From the first dose of study drug (Day 1) up to 60 days post last dose of study drug, up to 383 days

Secondary outcomes

  1. Change From Baseline to Weeks 24 and 48 in the COMPASS 31 (2-week Recall Version)

    Composite Autonomic Symptom Score (COMPASS) 31 modified version (2-week recall) is a self-rated questionnaire to evaluate the severity and distribution of autonomic symptoms in various autonomic nerve disorders. It consists of 31 questions in 6 weighted domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal {GI}-mixed upper and diarrhea, bladder, and pupillomotor). A weighted total score of 0 (mild) to 100 (severe) was determined by adding a maximum raw score for each domain. Higher scores indicated a more severe degree of autonomic symptoms.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  2. Change From Baseline to Weeks 24 and 48 in the MaPS

    The Malmö POTS Symptom Score (MaPS) score is a dedicated POTS symptom scoring questionnaire. The score consists of 12 questions that assess symptom burden related (tachycardia, palpitations, dizziness, presyncope) and unrelated to orthostatic intolerance (GI symptoms, insomnia, concentration difficulties). Participants graded their symptoms for the past 7 days using a numerical rating scale ranging from 0 (no symptoms) to 10 (very pronounced symptoms). The total score was calculated by summing up the items/individual items and range was 0 to 120 points, with higher scores indicating more severe symptoms.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  3. Percentage of Participants With Improved PGI-S at Weeks 24 and 48

    The Patient Global Impression-Severity (PGI-S) is a participant-rated, single-item scale to assess the severity of a health condition. The scale was used to assess the severity of symptoms over the past week (1-week recall) and overall experience of symptoms over the past 2 weeks (2-week recall). Both were rated on a 4-point type Likert scale, with scores ranging from 1 (none), 2 (mild), 3 (moderate), and 4 (severe). Higher scores indicate greater symptom severity. An "improved PGI-S" was defined by a change from baseline of -3, -2 and -1.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  4. Percentage of Participants With Improved PGI-C at Weeks 24 and 48

    The Patient Global Impression-Change (PGIC) is a single-item scale to capture the participant's perception of an overall change in their symptoms from start of study drug. It was rated on a 7-point Likert scale, with scores ranging from 1 (much better), 2 (somewhat better), 3 (a little better), 4 (no change), 5 (a little worse), 6 (somewhat worse), and 7 (much worse). Higher PGI-C scores signify worse outcome. An "improved PGI-C" was defined by a change from baseline of 1, 2 and 3.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  5. Change From Baseline to Weeks 24 and 48 in the PROMIS Fatigue Short Form 8a

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a assesses the impact and perceived fatigue during the last 7 days. This validated 8-question scale has 5 response options, with scores ranging from 1 (not at all) to 5 (very much). Total scores ranged from 8 to 40; higher scores indicated higher fatigue levels and were converted to a T-score with a mean of 50 and standard deviation of 10. A decrease in T-score (negative change from baseline) indicated improvement in fatigue.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  6. Change From Baseline to Weeks 24 and 48 in the PROMIS Cognitive Function Short Form 6a

    PROMIS Cognitive Function Short Form 6a assesses the frequency of cognitive difficulties experienced in the past 7 days. The questionnaire comprises 6 questions on subjective cognitive difficulties regarding a participant's concentration, memory, language, mental acuity, and perceived changes in cognitive functioning. The participant marks their response on a 5-point Likert scale (1: never and 5: very often). Scores ranged from 6 to 30; higher scores indicated worse perceived cognitive functioning and were converted to a T-score with a mean of 50 and standard deviation of 10. An increase in T-score (positive change from baseline) indicated better cognitive function.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  7. Percent Change From Baseline in Total IgG Levels at Weeks 24 and 48

    Blood samples for immunoglobulin G (IgG) analysis were collected at specified time points. Total IgG concentrations were quantified using validated methods at a central laboratory.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  8. Serum Concentration of Efgartigimod

    Serum samples were collected at specified timepoints to determine the concentration of efgartigimod.

    Time frame: Pre-dose at Baseline (Day 1) and Weeks 1, 4, 12 and 24

  9. Number of Participants With ADAs Against Efgartigimod

    Blood samples were collected at specified timepoints to assess anti-drug antibodies (ADAs) against efgartigimod. ADA incidence reported here was defined as total number of participants with treatment-induced and treatment-boosted ADA. Treatment-induced ADA was defined as a baseline negative sample and at least 1 positive post-baseline sample. Treatment-boosted ADA was defined as a baseline positive sample and the titer value increased 4-fold or more compared to baseline.

    Time frame: From the first dose of study drug (Day 1) up to Week 48

07

Results

Posted Oct 23, 2025
Limitations and caveats
This study was terminated not for safety concerns but because the parent study found that efgartigimod IV provided no efficacy benefit in adult participants with PC-POTS.

Participant flow

This open-label study was an extension of ARGX-113-2104 study (NCT05633407) and was conducted at 9 sites in the United States from 26-Jun-23 to 15-Aug-24 in participants with post-coronavirus disease 2019 (COVID-19) postural orthostatic tachycardia syndrome (PC-POTS).

Participant flow — Overall Study
MilestoneEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Started2013
Completed10
Not completed1913
Withdrew: Study terminated by sponsor1711
Withdrew: Withdrawal by subject11
Withdrew: Adverse event10
Withdrew: Other01

Outcome measures

PrimaryNumber of Participants With TEAEs, TESAEs and TEAESIs

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. An adverse event of special interest (AESI) was an AE of scientific and medical concern specific to the sponsor's product or program. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration.

Time frame:
From the first dose of study drug (Day 1) up to 60 days post last dose of study drug, up to 383 days
Reported as:
Count of participants · Participants
Number of Participants With TEAEs, TESAEs and TEAESIs
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
TEAEs1312
TESAEs00
TEAESIs75
SecondaryChange From Baseline to Weeks 24 and 48 in the COMPASS 31 (2-week Recall Version)

Composite Autonomic Symptom Score (COMPASS) 31 modified version (2-week recall) is a self-rated questionnaire to evaluate the severity and distribution of autonomic symptoms in various autonomic nerve disorders. It consists of 31 questions in 6 weighted domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal {GI}-mixed upper and diarrhea, bladder, and pupillomotor). A weighted total score of 0 (mild) to 100 (severe) was determined by adding a maximum raw score for each domain. Higher scores indicated a more severe degree of autonomic symptoms.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Mean · score on a scale
Change From Baseline to Weeks 24 and 48 in the COMPASS 31 (2-week Recall Version)
score on a scaleEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 2413.608 ± 29.70268.447 ± 18.1170
Week 481.780—
SecondaryChange From Baseline to Weeks 24 and 48 in the MaPS

The Malmö POTS Symptom Score (MaPS) score is a dedicated POTS symptom scoring questionnaire. The score consists of 12 questions that assess symptom burden related (tachycardia, palpitations, dizziness, presyncope) and unrelated to orthostatic intolerance (GI symptoms, insomnia, concentration difficulties). Participants graded their symptoms for the past 7 days using a numerical rating scale ranging from 0 (no symptoms) to 10 (very pronounced symptoms). The total score was calculated by summing up the items/individual items and range was 0 to 120 points, with higher scores indicating more severe symptoms.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Mean · score on a scale
Change From Baseline to Weeks 24 and 48 in the MaPS
score on a scaleEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 24-0.8 ± 22.0210.3 ± 24.95
Week 48-17.0—
SecondaryPercentage of Participants With Improved PGI-S at Weeks 24 and 48

The Patient Global Impression-Severity (PGI-S) is a participant-rated, single-item scale to assess the severity of a health condition. The scale was used to assess the severity of symptoms over the past week (1-week recall) and overall experience of symptoms over the past 2 weeks (2-week recall). Both were rated on a 4-point type Likert scale, with scores ranging from 1 (none), 2 (mild), 3 (moderate), and 4 (severe). Higher scores indicate greater symptom severity. An "improved PGI-S" was defined by a change from baseline of -3, -2 and -1.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With Improved PGI-S at Weeks 24 and 48
percentage of participantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 24, 1-week recall12.50
Week 24, 2-week recall12.50
Week 48, 1-week recall25.00
Week 48, 2-week recall25.00
SecondaryPercentage of Participants With Improved PGI-C at Weeks 24 and 48

The Patient Global Impression-Change (PGIC) is a single-item scale to capture the participant's perception of an overall change in their symptoms from start of study drug. It was rated on a 7-point Likert scale, with scores ranging from 1 (much better), 2 (somewhat better), 3 (a little better), 4 (no change), 5 (a little worse), 6 (somewhat worse), and 7 (much worse). Higher PGI-C scores signify worse outcome. An "improved PGI-C" was defined by a change from baseline of 1, 2 and 3.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With Improved PGI-C at Weeks 24 and 48
percentage of participantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 24100.0100.0
Week 48100.075.0
SecondaryChange From Baseline to Weeks 24 and 48 in the PROMIS Fatigue Short Form 8a

The Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a assesses the impact and perceived fatigue during the last 7 days. This validated 8-question scale has 5 response options, with scores ranging from 1 (not at all) to 5 (very much). Total scores ranged from 8 to 40; higher scores indicated higher fatigue levels and were converted to a T-score with a mean of 50 and standard deviation of 10. A decrease in T-score (negative change from baseline) indicated improvement in fatigue.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Mean · T-score
Change From Baseline to Weeks 24 and 48 in the PROMIS Fatigue Short Form 8a
T-scoreEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 243.0 ± 4.932.6 ± 9.74
Week 48-3.5 ± 3.421.0 ± 5.94
SecondaryChange From Baseline to Weeks 24 and 48 in the PROMIS Cognitive Function Short Form 6a

PROMIS Cognitive Function Short Form 6a assesses the frequency of cognitive difficulties experienced in the past 7 days. The questionnaire comprises 6 questions on subjective cognitive difficulties regarding a participant's concentration, memory, language, mental acuity, and perceived changes in cognitive functioning. The participant marks their response on a 5-point Likert scale (1: never and 5: very often). Scores ranged from 6 to 30; higher scores indicated worse perceived cognitive functioning and were converted to a T-score with a mean of 50 and standard deviation of 10. An increase in T-score (positive change from baseline) indicated better cognitive function.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Mean · T-score
Change From Baseline to Weeks 24 and 48 in the PROMIS Cognitive Function Short Form 6a
T-scoreEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 24-2.2 ± 7.36-4.0 ± 5.97
Week 48-8.0—
SecondaryPercent Change From Baseline in Total IgG Levels at Weeks 24 and 48

Blood samples for immunoglobulin G (IgG) analysis were collected at specified time points. Total IgG concentrations were quantified using validated methods at a central laboratory.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Mean · percent change
Percent Change From Baseline in Total IgG Levels at Weeks 24 and 48
percent changeEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 2432.684 ± 28.6347-59.636 ± 6.2440
Week 48-10.360—
SecondarySerum Concentration of Efgartigimod

Serum samples were collected at specified timepoints to determine the concentration of efgartigimod.

Time frame:
Pre-dose at Baseline (Day 1) and Weeks 1, 4, 12 and 24
Reported as:
Mean · microgram/milliliter (mcg/mL)
Serum Concentration of Efgartigimod
microgram/milliliter (mcg/mL)Efgartigimod-EfgartigimodPlacebo-Efgartigimod
Day 19 ± 4—
Week 110 ± 411 ± 4
Week 411 ± 412 ± 4
Week 123 ± 37 ± 6
Week 245 ± 52 ± 2
SecondaryNumber of Participants With ADAs Against Efgartigimod

Blood samples were collected at specified timepoints to assess anti-drug antibodies (ADAs) against efgartigimod. ADA incidence reported here was defined as total number of participants with treatment-induced and treatment-boosted ADA. Treatment-induced ADA was defined as a baseline negative sample and at least 1 positive post-baseline sample. Treatment-boosted ADA was defined as a baseline positive sample and the titer value increased 4-fold or more compared to baseline.

Time frame:
From the first dose of study drug (Day 1) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With ADAs Against Efgartigimod
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Number of Participants With ADAs Against Efgartigimod11

Adverse events

Collected over From the first dose of study drug (Day 1) up to 60 days post last dose of study drug, up to 383 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod-Efgartigimod0/20 (0%)0/20 (0%)13/20 (65%)
Placebo-Efgartigimod0/13 (0%)0/13 (0%)12/13 (92.3%)
Most frequent other events
Showing 10 of 62
Most frequent other events
EventEfgartigimod-EfgartigimodPlacebo-Efgartigimod
COVID-19Infections and infestations5/201/13
FatigueGeneral disorders2/203/13
NauseaGastrointestinal disorders3/202/13
Muscular weaknessMusculoskeletal and connective tissue disorders0/202/13
Back painMusculoskeletal and connective tissue disorders2/200/13
HeadacheNervous system disorders2/201/13
SyncopeNervous system disorders2/201/13
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/200/13
Ear discomfortEar and labyrinth disorders0/201/13
TinnitusEar and labyrinth disorders0/201/13

Baseline characteristics

Analysis was performed on full analysis set (FAS) which included all enrolled participants.

Age, Continuous
Age, Continuous(years)Efgartigimod-EfgartigimodPlacebo-EfgartigimodTotal
Mean33.2 ± 11.3838.0 ± 11.4035.1 ± 11.46
Sex: Female, Male
Sex: Female, Male(Participants)Efgartigimod-EfgartigimodPlacebo-EfgartigimodTotal
Female151126
Male527
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod-EfgartigimodPlacebo-EfgartigimodTotal
Asian101
Black or African American101
White161329
More than one race101
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod-EfgartigimodPlacebo-EfgartigimodTotal
Hispanic or Latino235
Not Hispanic or Latino181028
08

Study locations

9 sites
  • UC Sand Diego Sulpizio Cardiovascular Center
    La Jolla, California 92037, United States
  • Standford Movement Disorder Center
    Palo Alto, California 94304, United States
  • North Shore University HealthSystem
    Glenview, Illinois 60026, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University Hospitals, Neurology Clinical Trials
    Cleveland, Ohio 44106, United States
  • Apex Trials Group
    Fort Worth, Texas 76104, United States
  • Pioneer Clinical Research
    Rosharon, Texas 77583, United States
  • Metrodora Institute
    West Valley City, Utah 84119, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Aug 2024, 13 months.

Results were first posted in Oct 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2023
First posted
Jun 26, 2023
StartActual
Jun 20, 2023
Primary completionActual
Aug 15, 2024
CompletionActual
Aug 15, 2024
Results first posted
Oct 23, 2025
Last update
Oct 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05918978
Lead sponsor
argenx
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Jun 20, 2023
Primary completion
Aug 15, 2024
Completion
Aug 15, 2024
Results posted
Oct 23, 2025
Last update
Oct 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion